Idiopathic Pulmonary Fibrosis (Respiratory) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis – Drugs In Development, 2021, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 17, 45, 8, 123, 34 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 9 and 2 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).

– The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

AbbVie Inc

Abeome Corp

Accendatech Co Ltd

Accro BioScience (Suzhou) Co Ltd

AdAlta Ltd

Aeon Respire Inc

Afimmune Biopharma Ltd

Algernon Pharmaceuticals Inc

Altavant Sciences Inc

Altay Therapeutics Inc

Aluda Pharmaceuticals Inc

AmMax Bio Inc

Amniotics AB

Amplia Therapeutics Ltd

AnaMar AB

Angion Biomedica Corp

Annji Pharmaceutical Co Ltd

Apaxen

APIE Therapeutics Inc

Aqua Therapeutics Co Ltd

Aqualung Therapeutics Corp

Lung Therapeutics Inc

Max Biopharma Inc

MDI Therapeutics Inc

Medibiofarma SL

Medicenna Therapeutics Corp

Metagone Biotech Inc

Metera Pharmaceuticals Inc

METiS Pharmaceuticals

Mission Therapeutics Ltd

MitoImmune Therapeutics Inc

Moerae Matrix Inc

Shanghai Ark Biopharmaceutical Co Ltd

Shanghai Fosun Pharmaceutical (Group) Co Ltd

Shijiazhuang Sagacity New Drug Development Co Ltd

Shionogi & Co Ltd

Sichuan Haisco Pharmaceutical Co Ltd

Silurian Pharmaceuticals Inc

Surrozen Inc

Suzhou Zelgen Biopharmaceutical Co Ltd

Syndax Pharmaceuticals Inc

SynDevRx Inc

Taiho Pharmaceutical Co Ltd

Taiwan Liposome Co Ltd

TaiwanJ Pharmaceuticals Co Ltd

Telomere Therapeutics

Tetragenetics Inc

Theravance Biopharma Inc

Thirona Bio Inc

TiumBio Co Ltd

TRACON Pharmaceuticals Inc

Translate Bio Inc

United Therapeutics Corp

Unity Biotechnology Inc

Vectus Biosystems Ltd

Velvio GmbH

Vicore Pharma AB

Viridian Therapeutics Inc

Wuhan LL Science and Technology Development Co Ltd

X-Rx Inc

Xfibra Inc

Yungjin Pharm Co Ltd

Table of Contents

Table of Contents

Introduction

Idiopathic Pulmonary Fibrosis - Overview

Idiopathic Pulmonary Fibrosis - Therapeutics Development

Idiopathic Pulmonary Fibrosis - Therapeutics Assessment

Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development

Idiopathic Pulmonary Fibrosis - Drug Profiles

Idiopathic Pulmonary Fibrosis - Dormant Projects

Idiopathic Pulmonary Fibrosis - Discontinued Products

Idiopathic Pulmonary Fibrosis - Product Development Milestonesh

Appendix

List of Tables

List of Tables

Number of Products under Development for Idiopathic Pulmonary Fibrosis, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Idiopathic Pulmonary Fibrosis – Pipeline by AbbVie Inc, 2021

Idiopathic Pulmonary Fibrosis – Pipeline by Abeome Corp, 2021

Idiopathic Pulmonary Fibrosis – Pipeline by Accendatech Co Ltd, 2021

Idiopathic Pulmonary Fibrosis – Pipeline by Accro BioScience (Suzhou) Co Ltd, 2021

Idiopathic Pulmonary Fibrosis – Pipeline by AdAlta Ltd, 2021

Idiopathic Pulmonary Fibrosis – Pipeline by Aeon Respire Inc, 2021

Idiopathic Pulmonary Fibrosis – Pipeline by Afimmune Biopharma Ltd, 2021

Idiopathic Pulmonary Fibrosis – Pipeline by Algernon Pharmaceuticals Inc, 2021

Idiopathic Pulmonary Fibrosis – Pipeline by Altavant Sciences Inc, 2021

Idiopathic Pulmonary Fibrosis – Pipeline by Altay Therapeutics Inc, 2021

Idiopathic Pulmonary Fibrosis – Pipeline by Aluda Pharmaceuticals Inc, 2021

Idiopathic Pulmonary Fibrosis – Pipeline by AmMax Bio Inc, 2021

Idiopathic Pulmonary Fibrosis – Pipeline by Amniotics AB, 2021

Idiopathic Pulmonary Fibrosis – Pipeline by Amplia Therapeutics Ltd, 2021

Idiopathic Pulmonary Fibrosis – Pipeline by AnaMar AB, 2021

Idiopathic Pulmonary Fibrosis – Pipeline by Angion Biomedica Corp, 2021

Idiopathic Pulmonary Fibrosis – Pipeline by Annji Pharmaceutical Co Ltd, 2021

Idiopathic Pulmonary Fibrosis – Dormant Projects, 2021

Idiopathic Pulmonary Fibrosis – Discontinued Products, 2021

Idiopathic Pulmonary Fibrosis – Discontinued Products, 2021 (Contd..1)

List of Figures

List of Figures

Number of Products under Development for Idiopathic Pulmonary Fibrosis, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports